We are international
publications TEXT SIZE   

August 2000 Volume 3, Issue 10:
News & Notes - August 2000
Clinical Trials Resource on the Web

CenterWatch maintains extensive information on clinical trials on their site, currently tracking over 41,000 government and industry clinical trials, including 227 that pertain to multiple myeloma. To retrieve those listings, go to www.centerwatch.com, click on listing of clinical trials, then click on oncology, then select multiple myeloma from the list. The trials are listed by state, with links to more detailed information on each trial. You can also subscribe to an e-mail patient notification service to be apprised of future trials

Patient Advocacy Resource

The Patient Advocate Foundation is a nationwide organization whose mission is to help patients facing a health crisis. The group helps patients deal with such issues as denial of coverage by insurance companies and debt problems. Patients can contact PAF via www.patientadvocate.org or by calling (800) 532-5274.

Medicare Coverage of Transplants Info

Information regarding Medicare coverage of autologous stem cell transplants for multiple myeloma can be found at www.hcfa.gov/quality/8b3-c.htm and information regarding Medicare coverage of transplants for amyloidosis can be found at www.hcfa.gov/quality/8b3-c.htm.

Newsblaster.com Joins IMF Family

The IMF would like to thank the team at a href=newsblaster.com>Newsblaster.com, our Online News Distribution Partner, for generously waiving the quarterly registration fee for its Internet-based news distribution. Newsblaster is a revolutionary online media distribution system with a current reach of more than 30,000 media contacts. Now, the IMF will be able to more effectively distribute myeloma news and information to the media, as well as track which editors and reporters are reading the materials.

Early Bird Gets the Room

If you are planning to attend the IMF’s 10th Anniversary Gala, please secure your hotel reservations early, as October is a busy time of year in New York City. We look forward to seeing you there!

 related articles